TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21389753
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (COMB)
Study: 18492847
Drug: Infant milk
Normalized name: Infant milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant milk formula with 6 g/L short-chain galacto- and long-chain fructo-oligosaccharides (scGOS/lcFOS)
Study: 16872565
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg GHB (Xyrem) alone
Study: 16872565
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg GHB (Xyrem) combined with 0.6 g/kg ethanol
Study: 14600188
Drug: ETC-216 (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETC-216 (recombinant ApoA-I Milano/phospholipid complexes) at 15 mg/kg or 45 mg/kg
Study: 14600188
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment groups (ETC-216)
Study: 8609686
Drug: PRP-T vaccine
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-T vaccine given to mothers during the third trimester and infants at 2, 3, and 4 months of age
Study: 8609686
Drug: PRP-T vaccine
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-T vaccine given to mothers and inactivated poliovirus vaccine to infants
Study: 8609686
Drug: Meningococcal A
Normalized name: MENINGOCOCCAL A/B/C/W/Y (PENBRAYA) KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal A and C vaccine given to mothers and PRP-T to infants
Study: 17358099
Drug: esmolol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: esmolol 1.5 mg/kg
Study: 3883685
Drug: Flupentixol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupentixol (0.5 mg)
Study: 8438612
Drug: Oral vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vaccination
Study: 30738680
Drug: Intranasal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal vaccination
Study: 30092413
Drug: Expedited transfer
Normalized name: SET,TRANSFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expedited transfer to cardiac arrest center (CAC) with 24/7 access to interventional cardiology facilities, cooling, and goal-directed therapies
Study: 25265492
Drug: Dabrafenib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabrafenib (150 mg orally twice daily) and trametinib (2 mg orally once daily)
Study: 22356216
Drug: L-NAME (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME (10 mm)
Study: 22356216
Drug: Theophylline +
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline + L-NAME (4 mm + 10 mm)
Study: 21161118
Drug: Implant anchorage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant anchorage assisted self-ligating appliance (G1)
Study: 18057680
Drug: Clofibate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibate (100 mg/Kg) plus phototherapy
Study: 11441371
Drug: High-velocity leg
Normalized name: Crab leg
DrugBank: Crab leg (DB11011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-velocity leg exercises 3 times weekly with weekly increases in resistance combined with 45 minutes of moderate, nonresistance exercise weekly.
Study: 11441371
Drug: Moderate intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate intensity exercise 30 minutes daily, 6 days weekly (self-paced walking program).
Study: 11441371
Drug: High-velocity leg
Normalized name: Crab leg
DrugBank: Crab leg (DB11011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-velocity leg exercises 3 times weekly.
Study: 11441371
Drug: High-velocity leg
Normalized name: Crab leg
DrugBank: Crab leg (DB11011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-velocity leg exercises 3 times weekly and moderate intensity exercise.
Study: 2471213
Drug: 7.5% NaCl/6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% NaCl/6% Dextran 70 (HSD) solution
Study: 2471213
Drug: Lactated Ringers
Normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringers (LR) solution
Study: 22336631
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 to 7 mg/kg)
Study: 22336631
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 to 7 mg/kg) in participants heterozygous at rs5751876 and rs2298383
Study: 22336631
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 to 7 mg/kg) in participants minor homozygous at rs5751876 and rs2298383
Study: 22336631
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 to 7 mg/kg) in participants minor homozygous at rs2472304
Study: 20078830
Drug: Calcium supplements
Normalized name: CALCIUM SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplements (1500 mg calcium/day in 3 divided doses)
Study: 17610879
Drug: 600 mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mug oral misoprostol
Study: 16291468
Drug: Functional Assessment
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument
Study: 11991447
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D3 fixed combination (n = 199)
Study: 11991447
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus vitamin D3 separate combination (n = 190)
Study: 11991447
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D3 treatment (both fixed and separate combinations)
Study: 11991447
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D3 treatment
Study: 7590047
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection therapy with absolute ethanol
Study: 7590047
Drug: 0.1% epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% epinephrine and thrombin spray (control group)
Study: 2291869
Drug: Felodipine 10
Normalized name: felodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 10 mg ER once daily
Study: 25711158
Drug: Formulation 1
Normalized name: Recombivax HB, Hepatitis B vaccine (recombinant) adult formulation 10 MCG per 1 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation 1 (F1) - microencapsulated fish oil powder
Study: 25711158
Drug: Formulation 2
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation 2 (F2) - microencapsulated fish oil powder
Study: 25711158
Drug: Fish Oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish Oil Gel Capsules (FOGC)
Study: 9616533
Drug: Salbutamol inhaled
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol inhaled via Turbuhaler
Study: 9616533
Drug: Salbutamol inhaled
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol inhaled via pMDI
Study: 2115680
Drug: Fluvoxamine (100-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100-300 mg/day)
Study: 2115680
Drug: Maprotiline (100-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (100-300 mg/day)
Study: 2115680
Drug: Total Sleep
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Sleep Deprivation (TSD) before and after one week of antidepressant medication
Study: 30735073
Drug: OO (3
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OO (3 g/day)
Study: 28316177
Drug: Routine secondary
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine secondary treatment for 3 months
Study: 10811678
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg orally every 8 hours
Study: 10811678
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg orally every 8 hours plus Rifampin 300 mg orally every 12 hours
Study: 8594266
Drug: 50 mg/d
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/d of alpha tocopherol
Study: 8594266
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d of beta carotene
Study: 3891813
Drug: Optimal dose
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal dose levels of Methylphenidate
Study: 3891813
Drug: Fixed-dose and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose and milligram-per-kilogram comparisons
Study: 29661563
Drug: Home Medication
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home Medication Management Review (HMMR) service
Study: 28875866
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FeFum and NaFeEDTA (FeFum+NaFeEDTA)
Study: 25840875
Drug: Standard sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sedation (fentanyl 1 μg/kg + midazolam 0.03-0.04 mg/kg or midazolam only)
Study: 25840875
Drug: Propofol Target
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol Target Controlled Infusion (1.2-1.6 μg/ml)
Study: 23878443
Drug: Betahistine 16
Normalized name: betahistine 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 16 mg plus ondansetron 8 mg
Study: 23878443
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus ondansetron 8 mg
Study: 19514185
Drug: Drug group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug group (Nimodipine)
Study: 19514185
Drug: EA plus
Normalized name: Finacea Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA plus drug group (EA + Nimodipine)
Study: 15364709
Drug: docosahexaenoic acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docosahexaenoic acid (1200 mg/d) plus 15,000 IU/d of vitamin A (DHA + A group)
Study: 15364709
Drug: diet rich
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: diet rich in omega-3 fatty acids (>=0.20 g/d)
Study: 19486341
Drug: Coffee (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee (100 mg caffeine)
Study: 25171029
Drug: Autologous blood
Normalized name: Banked autologous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous blood injection (group A, n=50)
Study: 25171029
Drug: Diluted epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diluted epinephrine injection (group B, n=50)
Study: 22822992
Drug: MDZ (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDZ (0.02 mg/kg) followed by 0.01 mg/kg every 45 minutes + DEX (2 µg/kg/h for 10 minutes, then 0.5 µg/kg/h)
Study: 22822992
Drug: MDZ (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDZ (0.02 mg/kg) followed by 0.01 mg/kg every 45 minutes + DEX (1 µg/kg/h for 10 minutes, then 0.3 µg/kg/h)
Study: 22822992
Drug: MDZ (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDZ (0.03 mg/kg) followed by 0.01 mg/kg every 30 minutes + DEX (1 µg/kg/h for 10 minutes, then 0.3 µg/kg/h)
Study: 22822992
Drug: DEX (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX (2 µg/kg/h for 10 minutes, then 0.5 µg/kg/h) without MDZ
Study: 18978162
Drug: Probiotic capsules
Normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsules containing Lactobacillus rhamnosus LC705 and Propionibacterium freudenreichii ssp shermanii JS (2 x 10^10 colony forming units of each strain daily)
Study: 10692752
Drug: sumatriptan suppository
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sumatriptan suppository 6 mg
Study: 10692752
Drug: sumatriptan suppository
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sumatriptan suppository 12.5 mg
Study: 10692752
Drug: sumatriptan suppository
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sumatriptan suppository 25 mg
Study: 6310833
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with azathioprine and prednisolone (AP)
Study: 27993811
Drug: Salvage chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage chemotherapy with gemcitabine, dexamethasone, cisplatin (GDP) or dexamethasone, cytarabine, cisplatin (DHAP) followed by autologous stem cell transplantation (ASCT)
Study: 25040234
Drug: Oral cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cancer screening via mass media campaign and dental visits to a public hospital
Study: 3293828
Drug: Halofantrine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine (1000 mg followed by 500 mg 6 hours later)
Study: 3293828
Drug: Halofantrine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine (500 mg every 6 hours for 3 doses)
Study: 3293828
Drug: Mefloquine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (1000 mg single dose)
Study: 3293828
Drug: Mefloquine (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (1500 mg single dose)
Study: 31951819
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg D-cycloserine (DCS)
Study: 10781481
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg)
Study: 26155952
Drug: Active ultrasound
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ultrasound treatment by CellsonicTM on one arm (30 minutes, 5 treatments)
Study: 30543311
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (no treatment)
Study: 21517801
Drug: Low-dose 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose 5-fluorouracil 0.5%/salicylic acid 10.0% (Actikerall®)
Study: 16531594
Drug: Intervention by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention by firefighters (community-based intervention including a heart attack survival kit with aspirin)
Study: 14522812
Drug: Intense treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intense treatment for airway obstruction
Study: 14522812
Drug: Current therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current therapeutic options (ipratropium and corticosteroids with beta2 selective drugs)
Study: 10580176
Drug: Vegetable oil
Normalized name: Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable oil based stanols (3.8 g; 2.6 g sitostanol plus 1.2 g campestanol)
Study: 10580176
Drug: Pine wood
Normalized name: Pine wood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pine wood based stanols (4 g; 3.7 g sitostanol plus 0.3 g campestanol)
Study: 8849849
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ketorolac tromethamine
Study: 23360084
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg i.v.)
Study: 6149126
Drug: Propranolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (2 mg)
Study: 6149126
Drug: Oxprenolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (2 mg)
Study: 3511199
Drug: SnF2‐polycarboxylate cement
Approvals — FDA: no, EMA: no, PMDA: no
Description: SnF2‐polycarboxylate cement (72 mg F‐); placed in molars for 34 days (safety trial)
Study: 3511199
Drug: SnF2‐polycarboxylate restoration;
Approvals — FDA: no, EMA: no, PMDA: no
Description: SnF2‐polycarboxylate restoration; placed in molars during a 2 week period of no oral hygiene (efficacy trial)
Study: 3511199
Drug: Placebo restoration;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo restoration; placed in molars during a 2 week period of no oral hygiene (efficacy trial)
Study: 28098954
Drug: Play therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Play therapy
Study: 24998012
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg with telmisartan 80 mg
Study: 24998012
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg with rosuvastatin 20 mg
Study: 24998012
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (rosuvastatin and telmisartan)
Study: 24231013
Drug: Traditional total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional total parenteral nutrition
Study: 18923572
Drug: Ginseng (1125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng (1125 mg.d‐1)
Study: 16374152
Drug: Corticosteroids (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (50 mg hydrocortisone every 6 hrs and 50 microg of 9-alpha-fludrocortisone once a day for 7 days)
Study: 14609804
Drug: Risperidone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (1 mg to 3 mg/day)
Study: 14609804
Drug: Olanzapine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5 mg to 20 mg/day)
Study: 10338105
Drug: 12g piracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12g piracetam daily for 4 weeks and maintenance treatment for a further 8 weeks
Study: 1792797
Drug: Danazol 400
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 400 mg daily
Study: 1792797
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with prolactin antagonist and progesterone
Study: 6342126
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (12 patients) - antibiotics stopped for 18 months
Study: 6342126
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (11 patients) - received antibiotics when necessary for 18 months
Study: 8829024
Drug: Aspirin 81
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 mg once daily
Study: 30085149
Drug: Primaquine co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine co-administered with chloroquine
Study: 30085149
Drug: Primaquine co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine co-administered with dihydroartemisinin/piperaquine
Study: 30085149
Drug: Primaquine co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine co-administered with pyronaridine/artesunate
Study: 7979491
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (Genotropin) 30 IU/m2/week
Study: 1026550
Drug: Micro-encapsulated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-encapsulated aspirin (Levius)
Study: 24059744
Drug: Systemic doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic doxycycline (DOXY) 200 mg per day for 7 days
Study: 17973063
Drug: Evidence-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medicine course and case-method learning sessions (4 months, bi-weekly)
Study: 11141142
Drug: Cholesterol lowering
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol lowering treatments (dietary modification, drug treatment, or partial ileal bypass surgery for 1-10 years)
Study: 11141142
Drug: Dietary interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary interventions and non-statin drugs
Study: 9088856
Drug: Euglycaemic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Euglycaemic insulin clamp after heavy, glycogen-depleting exercise
Study: 9088856
Drug: Euglycaemic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Euglycaemic insulin clamp after resting control day
Study: 9156955
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg, once daily)
Study: 7522287
Drug: Nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine retard (20 mg, twice daily)
Study: 3324594
Drug: Single-dose antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose antibiotic prophylaxis (1 dose preoperatively)
Study: 3324594
Drug: Short-term antibiotic
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term antibiotic prophylaxis (1 dose preoperatively and 2 doses postoperatively)
Study: 26349433
Drug: Tonsillectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonsillectomy with steroid pulse therapy (TSP)
Study: 26349433
Drug: Steroid pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid pulse monotherapy
Study: 11015147
Drug: Nucleoside analogue
Normalized name: Nucleoside analogue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleoside analogue therapy
Study: 7958380
Drug: Intramuscular ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketorolac (10 mg)
Study: 7958380
Drug: Oral ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketorolac (10 mg)
Study: 6342641
Drug: Propranolol 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 320 mg/day
Study: 3113357
Drug: Verapamil 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 480 mg/day